Medical World News®: Nina Shah, MD, Discusses Peloton and the Importance of Exercise

Video

During an After Hours segment of Medical World News®, Nina Shah, MD, spoke about her new passion for Peloton, the convenience of working out from home, and the importance of getting out of the office for personal health and wellness.

Since the beginning of the COVID-19 pandemic, new and innovative ways to exercise have been needed. Because of this, the at-home workout brand, Peloton, became a household name by providing riders the opportunity to work out with others in the comfort of their own home.

Nina Shah, MD, from the University of California, San Francisco, down with CancerNetwork® to discuss why she enjoys Peloton so much, how exercise is a huge lift to her overall wellness, and why she thinks it’s important to find time to escape the office and focus on herself every day.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Recent Videos
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
AI-powered tools may help alleviate doctor burnout and give clinicians more time to directly engage with patients.
Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.
Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.
Related Content
An algorithm-based palliative care intervention provides a scalable implementation strategy to increase referrals in the community oncology setting.

Intervention Increases Palliative Cancer Care Consultations/Lowers EOL Care

Roman Fabbricatore
March 11th 2025
Article
Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO
March 10th 2025
Podcast

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Denosumab Biosimilars Approved by FDA for Previously Referenced Indications

Denosumab Biosimilars Approved by FDA for Previously Referenced Indications

Tim Cortese
March 5th 2025
Article

The FDA has approved 2 denosumab biosimilars for all prior approvals for the reference drugs in patients with cancers and osteoporosis.

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Psilocybin May Help Address Cancer-Related Psychological Concerns

Michael P. Bogenschutz, MD
January 20th 2025
Podcast

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Advanced Cancer Population Has Low Use of Supportive Care at End of Life

Advanced Cancer Population Has Low Use of Supportive Care at End of Life

Tim Cortese
March 3rd 2025
Article

A retrospective cohort study found that, of Medicare decedents with advanced cancer, 45% experienced potentially aggressive end-of-life care.

Phase 2 study results revealed NP-G2-044 plus standard of care anti–PD-1 therapy indicated treatment exhibited responses across at least 7 cancer types.

NP-G2-044 Elicits Durable Responses, Tumor Control in Advanced Solid Tumors

Roman Fabbricatore
February 28th 2025
Article

Phase 2 study results revealed NP-G2-044 plus standard of care anti–PD-1 therapy indicated treatment exhibited responses across at least 7 cancer types.